Equity Investment Corp Boosts Holdings in Sanofi $SNY

Equity Investment Corp grew its stake in Sanofi (NASDAQ:SNY) by 3.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,587,690 shares of the company’s stock after purchasing an additional 75,255 shares during the quarter. Sanofi makes up 2.6% of Equity Investment Corp’s holdings, making the stock its 12th biggest position. Equity Investment Corp owned about 0.11% of Sanofi worth $122,139,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of SNY. Thrivent Financial for Lutherans increased its holdings in shares of Sanofi by 10,152.1% in the third quarter. Thrivent Financial for Lutherans now owns 2,200,107 shares of the company’s stock valued at $103,846,000 after purchasing an additional 2,178,647 shares during the last quarter. Callodine Capital Management LP increased its stake in shares of Sanofi by 26.9% in the 2nd quarter. Callodine Capital Management LP now owns 515,209 shares of the company’s stock worth $24,890,000 after acquiring an additional 109,240 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of Sanofi by 17.0% during the 2nd quarter. Osaic Holdings Inc. now owns 188,526 shares of the company’s stock worth $9,189,000 after acquiring an additional 27,427 shares during the period. Arjuna Capital boosted its position in shares of Sanofi by 85.3% during the 3rd quarter. Arjuna Capital now owns 54,040 shares of the company’s stock valued at $2,551,000 after acquiring an additional 24,879 shares during the last quarter. Finally, Simon Quick Advisors LLC acquired a new position in shares of Sanofi during the 2nd quarter valued at about $246,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on SNY. Citigroup assumed coverage on shares of Sanofi in a research report on Tuesday, January 27th. They set a “neutral” rating for the company. Barclays lowered shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Wall Street Zen upgraded Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. Finally, UBS Group reaffirmed a “neutral” rating on shares of Sanofi in a research note on Friday, January 16th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $62.67.

Sanofi Stock Up 0.5%

NASDAQ:SNY opened at $47.49 on Wednesday. The company has a quick ratio of 0.29, a current ratio of 1.09 and a debt-to-equity ratio of 0.20. The stock’s fifty day moving average is $48.04 and its two-hundred day moving average is $48.68. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The stock has a market capitalization of $115.83 billion, a price-to-earnings ratio of 13.19, a price-to-earnings-growth ratio of 1.23 and a beta of 0.45.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.